Cargando…
Differential effects of ketoconazole on exposure to temsirolimus following intravenous infusion of temsirolimus
Intravenous (i.v.) temsirolimus, a novel inhibitor of mammalian target of rapamycin, is approved for the treatment of advanced renal cell carcinoma and is being studied in patients with mantle cell lymphoma. Because temsirolimus and its primary metabolite, sirolimus, are metabolised by the cytochrom...
| Autores principales: | , , , |
|---|---|
| Formato: | Texto |
| Lenguaje: | English |
| Publicado: |
Nature Publishing Group
2008
|
| Materias: | |
| Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2410110/ https://www.ncbi.nlm.nih.gov/pubmed/18458675 http://dx.doi.org/10.1038/sj.bjc.6604376 |